8-K: Scilex Holding Company Secures $50 Million Convertible Financing to Refinance Debt and Bolster Growth

Scilex Holding Company has finalized a $50 million registered convertible financing to refinance existing debt and strengthen its financial position.

Summary

• Scilex Holding Company has entered into a definitive agreement for a $50 million registered direct offering of convertible notes and warrants.
• The financing includes participation from affiliates of Murchinson, 3i LP, and existing senior debt holder, Oramed Pharmaceuticals, Inc.
• The offering is intended to refinance and restructure existing debt, positioning Scilex for long-term growth.
• Oramed will exchange a portion of its existing debt for a new convertible note.
• Scilex has made over $80 million in debt payments over the past 12 months.
• The new financing will allow Scilex to retire its revolving credit facility with eCapital Healthcare Corp.
• The notes have a 10% original issue discount, bear interest at 5.5% per annum, and mature in two years.
• The notes are convertible into common stock at $1.09 per share, subject to adjustments.
• Warrants to purchase 7,500,000 shares of common stock are included, exercisable at $1.09 per share.
• Net proceeds are expected to be approximately $20.5 million after deducting fees and expenses.
• The company intends to use the net proceeds to repay $12.5 million of the Oramed Note, payoff the eCapital facility, and for working capital.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful financing and debt restructuring. However, it also acknowledges the risks associated with the company's product development and market acceptance. The sentiment is cautiously optimistic.

Positives

• The financing is expected to strengthen Scilexs financial profile and position it for long-term growth.
• The company has successfully eliminated a $10 million loan with FSF 33433 LLC.
• The company has aggressively addressed and restructured its debt with payments of more than $80 million over the past 12 months.

Risks

• The offering is subject to customary closing conditions and may not close.
• The company may not be able to successfully market or gain market acceptance of its product candidates.
• The company may not be able to obtain required regulatory approvals for its product candidates.
• The company may not be able to replicate prior positive results of clinical trials.
• The company may have overestimated the size of the target patient population.

Future Outlook

The new financing is expected to position Scilex for sustainable, long-term growth and provide greater flexibility to operate under a strengthened financial position.

Management Comments

• We are thrilled to secure this new facility, which is expected to position Scilex to enter its next phase of our turnaround, enabling future growth and additional investment opportunities with much greater freedom and flexibility to operate under strengthened financial position.

Industry Context

This announcement reflects a trend in the pharmaceutical industry where companies are seeking to strengthen their balance sheets through strategic financing and debt restructuring to support growth and development of new therapies.

Comparison to Industry Standards

• The use of convertible notes and warrants is a common financing method for biotech companies, particularly those in the development stage.
• The interest rate of 5.5% is relatively standard for this type of financing, but the 10% original issue discount is a significant discount.
• The conversion price of $1.09 per share is subject to adjustment, which is a typical feature of convertible notes.
• The inclusion of warrants to purchase common stock is a common incentive for investors in such financings.
• The use of proceeds to pay off existing debt and for working capital is a typical use of funds from such financings.

Related Party Transactions

• Oramed, an existing senior debt holder, is participating in the financing and will exchange a portion of its existing debt for a new convertible note.
• Oramed will also acquire the right to receive an 8% royalty on the net sales of certain of Scilexs products for $2.5 million, which will be satisfied through a reduction of the outstanding principal balance on the Oramed Note.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of the notes and exercise of warrants.
• Creditors will benefit from the repayment of existing debt.
• Employees may benefit from the company's strengthened financial position and future growth opportunities.

Next Steps

• The company will use the net proceeds from the offering for repayment and satisfaction of $12.5 million of the outstanding balance under the Oramed Note, payoff of the revolving credit facility with eCapital Healthcare Corp, satisfaction of certain costs, fees and expenses of the purchasers of the notes and the collateral agent, and, to the extent there are any remaining proceeds, for working capital and general corporate purposes of the Company.
• The company will work to obtain the consent of the counterparties under the Development Agreement as promptly as practical following execution of this Term Sheet.
• The company will work to form Lido Dev Co. following the date hereof.

Key Dates

Keywords

convertible financing, debt refinancing, non-opioid pain management, convertible notes, warrants, registered direct offering, debt restructuring, ZTlido, ELYXYB, GLOPERBA, SP-102, SP-103, SP-104